Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vyvanse Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vyvanse in Children Aged 6 to 12 Years

NCT05416125
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Lisdexamfetamine Dimesylate, Lifestyle therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults

NCT00753012
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine, Lisdexamfetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 14, 2026, 9:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00337285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
Vyvanse (lisdexamfetamine dimesylate), NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis

NCT01615887
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
lisdexamfetamine sulfate, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

NCT01093963
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

NCT00922272
View directory record Official record
Conditions
Schizophrenia and Predominant Negative Symptoms
Interventions
SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT02034201
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

NCT01977625
View directory record Official record
Conditions
Menopause, Brain Activity, Cognition
Interventions
Lisdexamfetamine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00807222
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Sleep
Interventions
lisdexamfetamine dimesylate
Drug
Lead sponsor
Clinical Study Centers, LLC
Other
Eligibility
6 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

NCT00776555
View directory record Official record
Conditions
Healthy
Interventions
Lisdexamfetamine Dimesylate, Racemic mixture of dextroamphetamine and lisdexamfetamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

NCT01096680
View directory record Official record
Conditions
Sleep Deprivation
Interventions
SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

NCT01071044
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Cognitive Impairments
Interventions
Lisdexamfetamine Dimesylate, Placebo "30, 50 or 70 mg"
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 14, 2026, 9:15 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

NCT02659488
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Vyvanse, fMRI, Placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

NCT04599504
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Lisdexamfetamine Dimesylate (Medication), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 14, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

NCT00248092
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2007 · Synced Sep 14, 2026, 9:15 AM EDT
Terminated Phase 4 Interventional Results available

Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression

NCT01051440
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
21 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 14, 2026, 9:15 AM EDT